SK Biopharmaceuticals Co., Ltd. (326030.KS) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 13Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

42.9x

EV/EBITDA

26.6x

Market Cap

KRW 6.61T

MomentumView details →

1D Return

+0.12%

YTD Return

−30.50%

RSI (14)

51.7

ValuationView details →

P/E (Fwd)

42.9x

EV/EBITDA

26.6x

Market Cap

KRW 6.61T

RSI (14)

51.7

MomentumView details →

1D Return

+0.12%

YTD Return

−30.50%

ProfitabilityView details →

Gross Margin

91.89%

Net Margin

46.55%

EBITDA Margin

27.40%

ROE (TTM)

39.24%

ROA (TTM)

28.26%

Asset Turnover

0.63x

GrowthView details →

Revenue YoY

+38.86%

EPS YoY

+51.58%

FCF YoY

+173.36%

Revenue CAGR 3Y

+42.12%

EPS CAGR 3Y

+11.14%

EBITDA YoY

+0.51%

EarningsView details →

EPS (Actual)

KRW 581.55

EPS Surprise

3.17%

Beats (12Q)

1/12

Next Q EPS Est

KRW 594.78

Avg Surprise (4Q)

3.17%

Rev Surprise

5.80%

Capital & dividendView details →

Debt/Equity

0.05x

Current Ratio

2.72x

Quick Ratio

2.42x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

861.34B

Net Income (TTM)

400.96B

Op. CF (TTM)

251.61B

Next earningsNov 5, 2026 →

Latest newsMore news →

No recent news for 326030.KS.

Similar companies

Samsung Epis Holdings0126Z0.KS HLB Co., Ltd.028300.KQ PharmaResearch Co., Ltd.214450.KQ Peptron, Inc.087010.KQ LigaChem Biosciences Inc.141080.KQ Hugel, Inc.145020.KQ Find similar companies →

Latest newsMore news →

No recent news for 326030.KS.